Results 281 to 290 of about 4,346,534 (345)
Some of the next articles are maybe not open access.
Journal of Clinical Virology, 2006
The safety of the blood supply has been greatly improved in the past two decades owing to continuous improvement in the technology and sensitivity of laboratory testing, better donor education and selection, and tighter quality control on blood bank operations.
openaire +2 more sources
The safety of the blood supply has been greatly improved in the past two decades owing to continuous improvement in the technology and sensitivity of laboratory testing, better donor education and selection, and tighter quality control on blood bank operations.
openaire +2 more sources
Studies on the structure of HBV DNA.
Science in China. Series B, Chemistry, life sciences & earth sciences, 1989The structure of HBV adr NC-1 DNA is analyzed and compared with another five strains of HBV DNAs. Some of the prokaryotic promoter-like sequences, palindrom sequences and ATAA are found. An enhancer core sequence and some other characteristics are also shown.
Qi, ZH, Yan, J, Zhu, QL
openaire +3 more sources
Hepatobiliary & pancreatic diseases international : HBPD INT, 2004
To assess a sensitive and specific technique for detecting serum HBV DNA with an HBV DNA probe labelled directly by alkaline phosphatase (AlkPhos Direc probe).AlkPhos Direc probe was prepared with purified HBV DNA labelled directly by alkaline phosphatase. The probe and chemiluminescent substrate CDP-star for AP were used in hybridization assay.
Ya-Xi, Chen +4 more
openaire +2 more sources
To assess a sensitive and specific technique for detecting serum HBV DNA with an HBV DNA probe labelled directly by alkaline phosphatase (AlkPhos Direc probe).AlkPhos Direc probe was prepared with purified HBV DNA labelled directly by alkaline phosphatase. The probe and chemiluminescent substrate CDP-star for AP were used in hybridization assay.
Ya-Xi, Chen +4 more
openaire +2 more sources
Inhibition of HBV DNA Replication by Ganciclovir in Patients With AIDS.
Lancet, The, 1989I Gust, Ron Lucas, K Guo
exaly +3 more sources
An overview of assays for serum HBV DNA.
Clinical laboratory, 2001link_to_subscribed_fulltext
Ho, SKN, Chan, TM
openaire +2 more sources
Journal of Medical Virology, 2001
AbstractThe role of hepatitis B virus (HBV) in carcinogenesis of hepatitis B surface antigen (HBsAg)‐negative, anti‐hepatitis C virus (anti‐HCV)‐positive hepatocellular carcinoma (HCC) remains unknown. To investigate the state of HBV DNA in such HCC, HBV DNA was examined by polymerase chain reaction (PCR) between HBV DNA and human Alu sequence (HBV‐Alu
S, Kawai +4 more
openaire +2 more sources
AbstractThe role of hepatitis B virus (HBV) in carcinogenesis of hepatitis B surface antigen (HBsAg)‐negative, anti‐hepatitis C virus (anti‐HCV)‐positive hepatocellular carcinoma (HCC) remains unknown. To investigate the state of HBV DNA in such HCC, HBV DNA was examined by polymerase chain reaction (PCR) between HBV DNA and human Alu sequence (HBV‐Alu
S, Kawai +4 more
openaire +2 more sources
Enhancement of immune responses to an HBV DNA vaccine by electroporation
Vaccine, 2006These studies document the ability of electroporation (EP)-based DNA vaccination to induce multi-specific CTL responses to hepatitis B virus (HBV) DNA vaccination in normal mice and marked immune responses to multivalent HBV DNA immunization in larger animal species.
A, Luxembourg +4 more
openaire +2 more sources
Mapping of 5′ Ends of Virion-Derived HBV DNA
Virology, 1992Mapping of the 5' ends of virion-derived hepatitis B virus DNA molecules was carried out after cloning and sequencing linearized genomes made fully double stranded. Of five clones obtained, three of four minus strand termini mapped to the G in position 1826 and one to the T in position 1827.
J A, Saldanha +3 more
openaire +2 more sources
Treatment decisions based on
AbstractThe most common cause of hepatocellular carcinoma (HCC) worldwide is chronic hepatitis B virus (HBV) infection (CHB). Long‐term suppression of HBV replication by antiviral treatment reduces the risk of HCC and mortality. Nonetheless, only 2.2% of CHB patients globally received the treatment in 2019.
openaire +2 more sources

